EP0560055B1 - Immuno-suppressing enepyranose derivatives - Google Patents

Immuno-suppressing enepyranose derivatives Download PDF

Info

Publication number
EP0560055B1
EP0560055B1 EP93101822A EP93101822A EP0560055B1 EP 0560055 B1 EP0560055 B1 EP 0560055B1 EP 93101822 A EP93101822 A EP 93101822A EP 93101822 A EP93101822 A EP 93101822A EP 0560055 B1 EP0560055 B1 EP 0560055B1
Authority
EP
European Patent Office
Prior art keywords
substituted
alkyl
hydrogen atom
phenyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP93101822A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP0560055A1 (en
Inventor
Sadanori c/o Ishihara Sangyo Kaisha Mizukoshi
Fuminori c/o Ishihara Sangyo Kaisha Kato
Masamitsu c/o Ishihara Sangyo Kaisha Tsukamoto
Kenji c/o Ishihara Sangyo Kaisha Kon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ishihara Sangyo Kaisha Ltd
Original Assignee
Ishihara Sangyo Kaisha Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP4361752A external-priority patent/JPH06183965A/ja
Application filed by Ishihara Sangyo Kaisha Ltd filed Critical Ishihara Sangyo Kaisha Ltd
Publication of EP0560055A1 publication Critical patent/EP0560055A1/en
Application granted granted Critical
Publication of EP0560055B1 publication Critical patent/EP0560055B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • C07H13/06—Fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/08—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals directly attached to carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/12—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by acids having the group -X-C(=X)-X-, or halides thereof, in which each X means nitrogen, oxygen, sulfur, selenium or tellurium, e.g. carbonic acid, carbamic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/18—Acyclic radicals, substituted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/207—Cyclohexane rings not substituted by nitrogen atoms, e.g. kasugamycins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/08—Deoxysugars; Unsaturated sugars; Osones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/10—Anhydrosugars, e.g. epoxides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/02—Acyclic radicals

Definitions

  • the present invention relates to an enopyranose derivative of the formula (I) or its salt for use as an immuno-suppressive medicament or an anti-inflammatory medicament and a compound of the formula (I-1) or (I-2) and its salts.
  • An immuno-suppressive agent is usually used for treating a disease caused by abnormal sthenia of an immunological function, for example, a so-called autoimmune disease such as rheumatoid arthritis, systemic lupus erythematosus, chronic nephritis, chronic thyroiditis or autoimmune hemolytic anemia or for suppressing a rejection at the time of transplantation of an organ.
  • a so-called autoimmune disease such as rheumatoid arthritis, systemic lupus erythematosus, chronic nephritis, chronic thyroiditis or autoimmune hemolytic anemia or for suppressing a rejection at the time of transplantation of an organ.
  • steroid hormone, azathioprine and cyclophosphamide have been used as immuno-suppressive agents.
  • the present inventors have found that an enopyranose derivative having a chemical structure totally different from conventional immuno-suppressive agents, has immuno-suppressive activities.
  • the present invention has been accomplished an the basis of this discovery.
  • the present invention provides an enopyranose derivative of the following formula (I) or its salt for use as an immuno-suppressive medicament or an anti-inflammatory medicament: wherein R 1 is a hydrogen atom, C 1-20 alkyl which may be substituted with alkoxy such as methoxy or ethoxy, phenyl or hydroxyl, C 2-20 alkenyl, C 2-20 alkynyl, -OSO 2 R 7 , a halogen atom, -OCOR 7 , -NHCOR 8 , C 1-20 alkoxy, phenyl which may be substituted with halogen, alkyl such as methyl or ethyl, or nitro, or a residue represented by , R 2 is a hydrogen atom or C 1-20 alkyl, R 3 is a hydrogen atom or a halogen atom, R 4 is a hydrogen atom, -COR 9 , silyl which may be substituted with alkyl such as methyl, ethyl,
  • alkoxy such as methoxy or ethoxy, phenyl or hydroxyl
  • a residue represented by , C 3-8 cycloalkyloxy which may be substituted with alkoxy such as methoxy or ethoxy, phenyl or hydroxyl or -OCOR 10 and the other is a hydrogen atom or C 1-20 alkyl which may be substituted with alkoxy such as methoxy or ethoxy, phenyl or hydroxyl, or R 4 and R 5 together form a single bond
  • R 6 is a hydrogen atom or the C 1-20 alkyl which may be substituted with alkoxy such as methoxy or ethoxy, phenyl or hydroxyl
  • each of R 7 , R 9 and R 10 is C 1-20 alkyl or phenyl which may be substituted with halogen, alkyl such as methyl or ethyl, or nitro
  • R 8 is C 1-20 alkyl, phenyl which may be substituted with hal
  • Figure 1 is a graph showing the inhibiting effects of the compounds of the formula (I) an collagen-induced arthritis model.
  • the alkyl group represented by or the alkyl moiety of a functional group represented by each of R 1 , R 2 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , X and Y in the formula (I), may be C 1 -C 20 alkyl such as methyl, ethyl, propyl, butyl, pentyl, hexyl, hepthyl, octyl, nonyl, decyl, tetradecyl, pentadecyl, octadecyl or nonadecyl, and they include linear or branched aliphatic structural isomers.
  • the alkenyl group represented by each of R 1 , X and Y may be C 2 -C 20 alkenyl such as ethenyl, propenyl or butenyl, and they include linear or branched aliphatic structural isomers.
  • the alkynyl group represented by each of R 1 , X and Y may be C 2 -C 20 alkynyl such as ethynyl, propynyl or butynyl, and they also include linear or branched aliphatic structural isomers.
  • the halogen atom represented by each of R 1 and R 3 in the formula (I) may be a fluorine atom, a chlorine atom, a bromine atom or an iodine atom.
  • the saccharose residue represented by each of R 1 , R 5 and R 6 in the formula (I) may, for example, be:
  • the cycloalkyl group represented by or the cycloalkyl moiety of a cycloalkyloxy group represented by each of R 5 , R 6 and X in the formula (I), may be C 3 -C 8 cycloalkyl such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl.
  • the substituent for the phenyl which may be substituted may be a halogen atom such as fluorine, chlorine, bromine or iodine, alkyl such as methyl or ethyl, or nitro.
  • the substituent for the silyl which may be substituted, represented by R 4 in the formula (I), may be alkyl such as methyl, ethyl, propyl or butyl, or phenyl.
  • the substituent for the alkyl which may be substituted, the alkoxy which may be substituted, or the cycloalkyloxy which may be substituted, represented by each of R 1 , R 4 , R 5 and R 6 in the formula (I), may be alkoxy such as methoxy or ethoxy, phenyl or hydroxyl.
  • the number of such substituents may be one or more. If the number is two or more, such a plurality of substituents may be the same or different.
  • the substituent for the alkyl which may be substituted, the alkenyl which may be substituted or the alkynyl which may be substituted may be a halogen atom such as fluorine, chlorine, bromine or iodine, hydroxyl, phenyl, alkyl-substituted phenyl such as tolyl or xylyl, pyridyl, furanyl, thienyl, acyloxy such as acetoxy or valeroxy, azide, or amino.
  • the substituent for the cycloalkyl which may be substituted, the phenyl which may be substituted, the pyridyl which may be substituted, the furanyl which may be substituted or the thienyl which may be substituted may be a halogen atom such as a fluorine, chlorine, bromine or iodine, hydroxyl, alkyl such as methyl or ethyl, acyloxy such as acetoxy or valeroxy, nitro, or amino.
  • the number of such substituents may be one or more. When the number is two or more, such a plurality of substituents may be the same or different.
  • the chain hydrocarbon group for R 11 may be alkyl, alkenyl or alkynyl.
  • the monocyclic hydrocarbon group may be cycloalkyl, cycloalkenyl or phenyl.
  • the polycyclic hydrocarbon group may be a condensed polycyclic hydrocarbon group such as naphthyl, tetrahydronaphthyl or indanyl, or a bridged polycyclic hydrocarbon group such as adamantyl, noradamantyl, norbornanyl or norbornanonyl.
  • the monocyclic heterocycle group may be pyrrolyl, furanyl, thienyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrrolinyl, pyrrolidinyl, dihydrofuranyl, tetrahydrofuranyl, dihydrothienyl, tetrahydrothienyl, pyrazolinyl, hydantoinyl, oxazolinyl, isoxazolinyl, isoxazolidinyl, thiazolinyl, thioazolidinyl, dioxolanyl, dithiolanyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, dihydropyridyl, tetrahydropyridyl, piperidinyl
  • the polycyclic heterocycle group may be a condensed polycyclic heterocycle group such as thienothienyl, dihydrocyclopentathienyl, indolyl, benzofuranyl, benzothienyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzimidazolyl, tetrahydrobenzothienyl, dihydrobenzofuranyl, tetrahydrobenzisoxazolyl, benzodioxolyl, quinolinyl, isoquinolinyl, benzodioxanyl or quinoxalinyl, or a bridged polycyclic heterocycle group such as quinuclidinyl.
  • the substituent for the chain hydrocarbon group which may be substituted for R 11 may be a halogen atom, alkoxy, haloalkoxy, alkylthio, cycloalkyl, cycloalkoxy, cycloalkenyl, cycloalkenyloxy, alkoxycarbonyl, carboxyl, alkylcarbonyl, alkylcarbonyloxy, aryl, aryloxy, arylthio, amino, alkyl-substituted amino.
  • the number of such substitutents or substituents on such substitutents may be one or more. When the number is two or more, such a plurality of substituents may be the same or different.
  • the substituent for the monocyclic hydrocarbon group which may be substituted, the polycyclic hydrocarbon group which may be substituted, the monocyclic heterocycle group which may be substituted, or the polycyclic heterocycle group which may be substituted for R 11 may be a halogen atom, alkyl, haloalkyl, alkoxy, haloalkoxy, alkylthio, cycloalkyl, cycloalkoxy, cycloalkenyl, cycloalkenyloxy, alkoxycarbonyl, alkylcarbonyl, alkylcarbonyloxy, aryl, aryloxy, arylthio, amino, alkyl-substituted amino, cyano, nitro or hydroxyl.
  • the number of such substituents or substituents on such substituents may be one or more. When the number is two or more, such a plurality of substituents may be the same or different.
  • the alkyl group or the alkyl moiety contained in R 11 may be C 1 -C 18 alkyl such as methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, decyl or nonadecyl, and they include linear or branched aliphatic structural isomers.
  • the alkenyl contained in R 11 may be C 2 -C 18 alkenyl such as vinyl, propenyl, butenyl, pentenyl,-hexenyl, decenyl or nonadecenyl, and they include linear or branched aliphatic structural isomers.
  • the alkynyl group contained in R 11 may be C 2 -C 18 alkynyl such as ethynyl, propynyl, butynyl, pentynyl, hexynyl, decynyl or nonadecynyl, and they include linear or branched aliphatic structural isomers.
  • the cycloalkyl group or the cycloalkyl moiety contained in R 11 may be C 3 -C 8 cycloalkyl such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloctyl.
  • the cycloalkenyl or the cycloalkenyl moiety contained in R 11 may be C 5 -C 8 cycloalkenyl such as cyclopentenyl, cyclohexenyl or cycloctenyl.
  • the halogen atom contained in R 11 may be a fluorine atom, a chlorine atom, a bromine atom or an iodine atom.
  • the aryl group or the aryl moiety contained in R 11 may be phenyl, thienyl, furanyl, pyridyl, naphthyl, benzothienyl, benzofuranyl or quinolinyl.
  • the enopyranose derivatives of the formula (I) have stereoisomers, since the carbon atoms at the 1-, 2- and 5-positions of the pyranose ring are asymmetric carbon atoms, and such stereoisomers are also useful for the present invention.
  • the salt of an enopyranose derivative of the formula (I) may be an acid addition salt with a mineral acid such as hydrochloric acid or sulfuric acid.
  • the enopyranose derivative of the formula (I) is preferably the following:
  • Enopyranose derivatives of the formula (I) include novel compounds.
  • the present invention provides the following compounds as such novel compounds.
  • the present invention provides a compound of the following formula (I-1) or (I-2) : wherein R 1 is a hydrogen atom, alkyl which may be substituted, alkenyl, alkynyl, -OSO 2 R 7 , a halogen atom, -OCOR 7 , -NHCOR 8 , alkoxy, phenyl which may be substituted or a saccharose residue, R 2 is a hydrogen atom or alkyl, R 3 is a hydrogen atom or a halogen atom, R 4 and R 5 together form a single bond, R 6 is a hydrogen atom or alkyl which may be substituted, R 7 is alkyl or phenyl which may be substituted, R 8 is alkyl, phenyl which may be substituted or benzyloxy, X is a hydrogen atom, alkyl which may be substituted, alkenyl which may be substituted, alkynyl which may be substituted, cycloalkyl which
  • the enopyranose derivative of the formula (I) or its salt can be prepared by various methods. For example, 1,6-anhydro-3,4-dideoxy- ⁇ -D-glycero-hex-3-enopyranos-2-ulose is reduced to obtain 1,6-anhydro-3,4-dideoxy- ⁇ -D-threo-hex-3-enopyranose, which is then acylated, carbonated, carbamated, etherified or sulfonylated by a conventional method to obtain a desired compound.
  • the 2-position of 1,6-anhydro-3,4-dideoxy- ⁇ -D-glycero-hex-3-enopyranos-2-ulose is alkylated, alkenylated or alkynylated by a conventional method to obtain a desired compound. Further, this 2-position reaction product may be acylated, carbonated, carbamated, etherified or sulfonylated as mentioned above to obtain a desired compound.
  • 1,6-anhydro-3,4-dideoxy- ⁇ -D-erythro-hex-3-enopyranose can be obtained also by the above-mentioned reduction reaction.
  • the product can be prepared also by isomerization of the above-mentioned threo-isomer. Further, the product may be acylated, carbonated, carbamated, etherified or sulfonylated by a conventional method to obtain a desired compound.
  • a compound of the following formula (II) may be used instead of 1,6-anhydro-3,4-dideoxy- ⁇ -D-glycero-hex-3-enopyranos-2-ulose.
  • R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are as defined above.
  • the compound of the formula (II) is reduced, or alkylated, alkenylated or alkynylated by a conventional method and acylated, carbonated, carbamated, etherified or sulfonylated by a conventional method to obtain a desired compound. Otherwise, the compound of the formula (II) may be reduced and then isomerized, and acylated, carbonated, carbamated, etherified or sulfonylated by a conventional method to obtain a desired compound.
  • the compound of the formula (II) has an enantiomer (L-isomer), and the same reaction as mentioned above can be conducted by using this enantiomer.
  • the reaction mixture is stirred and reacted at a temperature of not higher than room temperature, preferably from -10 to 0°C, for from 0.5 to 2 hours. After adding a small amount of water, the reaction product is post-treated by a conventional method for purification and separation.
  • a suitable acyl halide is gradually added in an amount of at least 1 equivalent, preferably from 1.5 to 2 equivalent, to a dry pyridine solution containing a reduced product of 1,6-anhydro-3,4-dideoxy- ⁇ -D-glycerohex-3-enopyranos-2-ulose or its 2-position reaction product.
  • the reaction mixture is stirred and reacted at a temperature of not higher than room temperature, preferably from -10 to 0°C, for from 0.5 to 2 hours.
  • the reaction product is concentrated under reduced pressure to obtain a crude product, which is then purified and separated by a conventional method.
  • acylation is directly conducted by means of a carboxylic acid instead of an acyl halide
  • from 1.5 to 2 equivalent of dicyclohexylcarbodiimide or diethylcarbodiimide, from 1.5 to 2 equivalent of a suitable carboxylic acid and from 0.1 to 0.2 equivalent of N,N-dimethylaminopyridine or diisopropylethylamine as a catalyst are added to a dry methylene chloride solution containing 1,6-anhydro-3,4-dideoxy- ⁇ -D-threo-hex-3-enopyranose, and the reaction is conducted under stirring at a temperature of from 0 to 30°C, preferably from 10 to 20°C, for from 6 to 12 hours.
  • the reaction product is post-treated by a conventional method for purification and separation.
  • At least 2 equivalent, preferably from 2 to 3 equivalent, of a suitable chlorocarbonate is gradually added to a dry pyridine solution containing the reduced product of 1,6-anhydro-3,4-dideoxy- ⁇ -D-glycero-hex-3-enopyranos-2-ulose or its 2-position reaction product, and the reaction mixture is stirred and reacted at a temperature of from 0 to 30°C, preferably from 10 to 20°C, for from 6 to 12 hours. After adding a small amount of water, the reaction product is post-treated by a conventional method for purification and separation.
  • At least 1.3 equivalent, preferably from 1.5 to 2 equivalent, of a suitable isocyanate or isothiocyanate is gradually added to a dry toluene solution containing the reduced product of 1,6-anhydro-3,4-dideoxy- ⁇ -D-glycero-hex-3-enopyranos-2-ulose or its 2-position reaction product, and the mixture is stirred for from 10 to 15 minutes. Then, from 0.1 to 0.2 equivalent of the diisopropylethylamine, triethylamine or the like, or from 0.8 to 1.2 equivalent of sodium hydride, potassium hydride or the like is added-thereto, and the mixture is further stirred and reacted. In the case of a reaction where triethylamine or the like is added, refluxing under heating is required.
  • reaction product is post-treated by a conventional method for purification and separation.
  • the reduced product of 1,6-anhydro-3,4-dideoxy- ⁇ -D-glycero-hex-3-enopyranos-2-ulose or its 2-position reaction product is gradually added to a dry tetrahydrofuran suspension containing from 1.0 to 1.5 equivalent, preferably 1.3 equivalent, of a base such as sodium hydride or potassium hydride.
  • the reaction mixture is stirred at a temperature of from 0 to 20°C, preferably from 0 to 10°C, for from 10 to 15 minutes, and then at least 1 equivalent, preferably from 1.3 to 1.5 equivalent, of a suitable organic halide is added thereto.
  • the mixture is stirred and reacted at a temperature of from 10 to 30°C, preferably from 20 to 30°C for from 6 to 12 hours.
  • the above-mentioned organic halide may be selected depending upon the desired object, and it may, for example, be methyl iodide, butyl iodide or benzyl bromide.
  • the reaction product is concentrated under reduced pressure to obtain a crude product, which is then subjected to purification and separation by a conventional method.
  • At least 1 equivalent, preferably from 1.5 to 2 equivalent, of a suitable sulfonyl halide is gradually added to a dry pyridine solution containing the reduced product of 1,6-anhydro-3,4-dideoxy- ⁇ -D-glycero-hex-3-enopyranos-2-ulose or its 2-position reaction product, and the reaction mixture is stirred and reacted at a temperature of from 10 to 30°C, preferably from 20 to 30°C, for from 6 to 12 hours.
  • the above-mentioned sulfonyl halide is selected depending upon the desired object, and it may, for example, be p-toluenesulfonyl chloride, methanesulfonyl chloride.
  • the reaction product was extracted with a solvent such as toluene. Then, the solvent is distilled off under reduced pressure to obtain a crude product, which is then subjected to purification and separation by a conventional method.
  • alkenylation or alkynylation organic metal reagent such as a suitable alkyl, alkenyl or alkynyl lithium or an alkyl, alkenyl or alkynyl magnesium bromide
  • a dry tetrahydrofuran solution containing 1,6-anhydro-3,4-dideoxy- ⁇ -D-glycero-hex-3-enopyranos-2-ulose.
  • the reaction mixture is stirred and reacted at a temperature of from -78 to 0°C, preferably from -10 to 0°C, for from 0.5 to 1 hour.
  • the reaction mixture is concentrated under reduced pressure to obtain a crude product, which is subjected to purification and separation by a conventional method.
  • a metal salt of a carboxylic acid such as sodium benzoate
  • a dry N,N-dimethylformamide solution of a p-toluenesulfonyl ester of the reduced product of 1,6-anhydro-3,4-dideoxy- ⁇ -D-glycero-hex-3-enopyranos-2-ulose or its 2-position reaction product is stirred and reacted at a temperature of from 100 to 150°C, preferably at a refluxing temperature, for 30 minutes.
  • the reaction mixture is post-treated by a conventional method to remove the solvent and then dissolved in dry methanol.
  • a base is added thereto, and the mixture is stirred and reacted at a temperature of from 0 to 30°C, preferably from 20 to 30°C, for 30 minutes.
  • the above-mentioned base may, for example, be sodium hydroxide, potassium hydroxide or sodium methoxide.
  • the reaction product is post-treated by a conventional method for purification and separation.
  • the compound of the above-mentioned formula (II) can be produced by various methods.
  • the 3-position of 1,6-anhydro-3,4-dideoxy- ⁇ -D-glycero-hex-3-enopyranos-2-ulose is halogenated to obtain a desired compound, and this 3-position reaction product is alkylated, alkenylated, alkynylated or aryl-modified by a coupling reaction to obtain a desired compound.
  • 1,6-anhydro-3,4-dideoxy- ⁇ -D-glycero-hex-3-enopyranos-2-ulose or its 3-position 4-position or 5-position substituted derivative is treated under an acidic condition to conduct ring opening of acetal and etherification at the 1-position simultaneously, or acylated at the 1-position and 6-position, to obtain a desired compound.
  • the 6-position of the compound having the 1-position etherified is etherified, acylated or silylated to obtain a desired compound.
  • the obtained compound may be hydrolyzed for deacylation at the 1-position or at the 1- and 6-positions.
  • a natural saccharose such as glucose, galactose or mannose
  • its 2-keto derivative is prepared by an oxidation reaction to obtain a desired enone derivative having an oxygen or nitrogen functional group at the 3-position.
  • At least 0.9 equivalent, preferably from 1.5 to 2 equivalent, of bromine is slowly added at a temperature of not higher than 0°C, preferably from -10 to -15°C to a carbon halide solution such as dry carbon tetrachloride or chloroform containing 1,6-anhydro-3,4-dideoxy- ⁇ -D-glycero-hex-3-enopyranos-2-ulose.
  • the reaction mixture is stirred and reacted at a temperature of not higher than 0°C, preferably from -10 to -15°C, for from 10 to 30 minutes.
  • the reaction mixture is stirred and reacted at room temperature, preferably from 15 to 25°C, for two hours. After adding ethyl acetate, the reaction mixture is post-treated by a conventional method for purification and separation.
  • a palladium catalyst such as dichlorobis(benzonitrile)palladium(II
  • an organotin compound or an organozinc compound is added, and the reaction is conducted at a temperature of from 0 to 100°C, preferably from 25 to 80°C, for from 1 to 10 hours, preferably from 2 to 6 hours.
  • the reaction product was post-treated by a conventional method for purification and separation. With respect to this method, the synthesis can be conducted in accordance with the method by C. R. Johnson et al. (Tetrahedron Lett., 33, 919-922 (1992)). Further, in a case where R 1 in the formula (II) is alkyl which may be substituted, the following method may be employed.
  • 1,6-anhydro-3-bromo-3,4-dideoxy- ⁇ -D-glycero-hex-3-enopyranos-2-ulose is reacted together with at least 1 equivalent of ethylene glycol and a catalytic amount of p-toluenesulfonic acid at a refluxing temperature of a solvent such as benzene or toluene to obtain 1,6-anhydro-3-bromo-3,4-dideoxy- ⁇ -D-glycero-hexo-3-enopyranos-2-ulose ethylene acetal having the carbonyl group at the 2-position of the pyranose ring protected.
  • this product is reacted in a solvent such as tetrahydrofuran together with at least one equivalent of n-butyl lithium and at least one equivalent of an alkyl iodide at a reaction temperature of from -60 to -80°C.
  • a solvent such as tetrahydrofuran together with at least one equivalent of n-butyl lithium and at least one equivalent of an alkyl iodide at a reaction temperature of from -60 to -80°C.
  • the protecting group at the 2-position of the pyranose ring is removed by a catalytic amount of p-toluenesulfonic acid at a refluxing temperature of tetrahydrofuran and water.
  • various ketones or aldehydes may be employed. In such a case, a compound wherein R 1 is an alkyl group substituted by a hydroxyl group, will be obtained.
  • the hydroxyl moiety of a hydroxyl-substituted alkyl group can be converted to an alkoxy group such as methoxy. Further, the hydroxy moiety of the hydroxyl-substituted alkyl group may be aminated by a conventional method.
  • a Lewis acid such as sulfuric acid or boron trifluoride etherate
  • a suitable acid anhydride containing 1,6-anhydro-3,4-dideoxy- ⁇ -D-glycero-hex-3-enopyranos-2-ulose or its 1-position, 3-position, 4-position or 5-position substituted derivative or to a dry chloroform solution of such an acid anhydride.
  • the reaction mixture is stirred for 10 minutes to 2 hours, preferably from 15 to 30 minutes.
  • the reaction solution is added to an ice-cooled saturated sodium bicarbonate solution and then treated by a conventional method for purification and separation (Carbohydr. Res., 71, 169-191 (1979)).
  • a 1-alkoxy derivative from 1 to 5%, preferably from 3 to 4%, of concentrated sulfuric acid is added to a solution of a corresponding alcohol such as methanol, ethanol or propanol, and the mixture is stirred at a temperature of from 10 to 30°C, preferably from 15 to 25°C, for from 5 to 48 hours, preferably from 12 to 36 hours.
  • the reaction solution is neutralyzed with a base such-as sodium hydrogencarbonate and then treated by a conventional method for purification and separation.
  • the alcohol at the 6-position formed can be converted by a conventional method such as etherification or acylation to a corresponding derivative.
  • a base such as lithium hydroxide, sodium hydroxide or potassium hydroxide
  • a base such as lithium hydroxide, sodium hydroxide or potassium hydroxide
  • a base such as lithium hydroxide, sodium hydroxide or potassium hydroxide
  • a base such as lithium hydroxide, sodium hydroxide or potassium hydroxide
  • a solution of water or an alcohol such as methanol, ethanol or isopropanol, containing 1,6-di-O-acyl-3,4-dideoxy- ⁇ -D-glycero-hex-3-enopyranos-2-ulose or its 1-position, 3-position, 4-position or 5-position substituted derivative
  • the mixture is stirred at a temperature of from 10 to 30°C, preferably from 15 to 25°C, for from 10 to 45 minutes, preferably from 20 to 30 minutes.
  • Ethyl acetate is added to the reaction product, and then the precipitate is removed by filtration. The filtrate is concentrated under reduced pressure to obtain a product, which is subjecte
  • the compounds of the formula (II) contain compounds which have not been disclosed in literatures.
  • H/OH and OH/H for R 5 and R 6 mean that either R 5 or R 6 is an OH group.
  • SitBuMe 2 represents a tert-butyl dimethylsilyl group
  • C 4 H 9 t represents a tert-butyl group
  • C 3 H 7 i represents an iso-propyl group.
  • Tr represents a triphenylmethyl group, and represents a cyclohexyl group.
  • 0.1 ml of concentrated sulfuric acid was added to 30 ml of a dry methanol solution containing 500 mg of 1,6-anhydro-3,4-dideoxy-3-methyl- ⁇ -D-glycero-hex-3-enopyranos-2-ulose (Intermediate No. 2), and the mixture was stirred at room temperature for 48 hours. Then, 30 ml of a saturated sodium hydrogencarbonate aqueous solution was added thereto, and the mixture was stirred at room temperature for 15 minutes and then concentrated under reduced pressure. Then, 200 ml of ethyl acetate was added thereto, and the mixture was washed three times with 200 ml of a saturated sodium chloride aqueous solution.
  • the serenium derivative obtained by the above reaction was dissolved in 20 ml of dry methylene chloride under an inert atmosphere of nitrogen gas, and 60 mg of m-chloroperbenzoic acid was added thereto at -78°C. The mixture was stirred for 20 minutes and then a saturated sodium hydrogencarbonate aqueous solution was added. The mixture was extracted twice with methylene chloride. The organic layers were put together and washed twice with a saturated sodium chloride aqueous solution and then dried over anhydrous sodium sulfate. The solvent was distilled off under reduced pressure.
  • the obtained crude product was dissolved in 200 ml of ethyl acetate, and the solution was washed three times with 200 ml of a saturated sodium chloride aqueous solution. The organic layer was dried over anhydrous sodium sulfate, and then the solvent was distilled off under reduced pressure.
  • the NMR analytical data of this product are as follows.
  • phenyl isocyanate 0.56 g was added at room temperature to 30 ml of a dry toluene solution containing 0.3 g of 1,6-anhydro-3,4-dideoxy- ⁇ -D-threo-hex-3-enopyranose under an inert atmosphere of nitrogen gas. Further, 0.1 ml of triethylamine was added thereto, and the reaction mixture was refluxed under heating for two hours. Completion of the reaction was confirmed by thin layer chromatography, and then the solvent was immediately distilled off under reduced pressure to obtain a syrup crude product.
  • methyl thioisocyanate was added to 30 ml of a dry toluene solution containing 0.35 g of 1,6-anhydro-3,4-dideoxy- ⁇ -D-threo-hex-3-enopyranose under an inert atmosphere of nitrogen gas. Then, sodium hydride (60% dispersion in mineral oil, 1.3 equivalent) was gradually added thereto. After confirming the termination of the generation of hydrogen (from 5 to 10 minutes), the stirring was further continued for one hour. Completion of the reaction was confirmed by thin layer chromatography, and then a small amount of water was added to inactivate sodium hydride. Then, the formed precipitate was removed by filtration with Celite®-anhydrous sodium sulfate.
  • the NMR analytical data of this product are as follows.
  • a condensation reaction of 16-tert-butyldimethylsilyloxyhexadecanoic acid obtained by the above reaction and Compound No. 1, was conducted in the same manner as in the above Preparation Example 3. Posttreatment was conducted by a conventional method, and then purification was conducted by silica gel column chromatography (ethyl acetate: hexane 1:7). The product was dissolved in 50 ml of dry tetrahydrofuran, and 3 ml of a tetrahydrofuran solution of 1N tetrabutyl ammonium fluoride, was added thereto at room temperature. The mixture was stirred for 12 hours.
  • H/OH and OH/H for R 5 and R 6 mean that either R 5 or R 6 is an OH group.
  • SitBuMe 2 represents a tert-butyl dimethylsilyl group
  • C 4 H 9 t represents a tert-butyl group
  • C 3 H 7 i represents an iso-propyl group.
  • Tr represents a triphenylmethyl group, and represents a cyclohexyl group.
  • mice of from 4 to 6 weeks old were used in groups each consisting of four mice.
  • An emulsion of bovine collagen type II (Product No. K41, manufactured by Collagen Gijutsu-Kenshukai) (3 mg/ml) in the same amount by volume of complete Freund's adjuvant (Product No. 642851, manufactured by ICN Immunobiologicals) was injected intradermally at the base of the tail of each mouse (150 ⁇ g/0.1 ml/mouse) to induce collagen-induced arthritis.
  • the degree of arthritis was evaluated under the following standards and represented by scores (from 0 to 3 points per foot, the maximum of 12 points as the total score of four feet):
  • 3 H-thymidine hereinafter referred to simply as 3 H-TdR
  • 3 H-TdR 3 H-thymidine
  • dpm radioactivity of 3 H-TdR uptaken into cells
  • Such measured amounts of 3 H-TdR uptaken into the cells were used as indices of the mitogenic response of the murine thymocytes, and the radioactivity at each concentration (from 0.001 to 1,000 ⁇ g/ml) of the compound of the formula (I) was compared with the control value treated solely by Con A, to calculate IC 50 value.
  • Tables 12 and 13 the results of murine thymocytes are shown by (a).
  • spleen cells of BALB/c and C57BL/6 mice were mixed in an equal amount of 5 ⁇ 10 5 cells each, and the mixed cells were cultured together with the compound of the formula (I) for 48 hours on a microplate with 96 wells by a 10% FCS-RPMI solution (in an incubator, 5% CO 2 , at 37°C). Then, 0.5 ⁇ Ci of 3 H-TdR was added thereto, and the mixture was further cultured for from 16 to 18 hours.
  • Bone mallow cells were removed from the femur of a BALB/c mouse and suspended in a 10% FCS-RPMI solution.
  • the cell suspension was put into a plastic Petri dish having a diameter of 10 cm and left to stand still (in an incubator, 5% CO 2 , at 37°C). Two hours later, only floating cells were recovered, and adhesion cells were removed. 1 ⁇ 10 5 floating cells were cultured for 48 hours together with a 20% culture supernatant of L929 fibroblastoma and the compound of the formula (I) on a microplate with 96 wells by a 10% FCS-RPMI solution (in an incubator, 5% CO 2 , at 37°C).
  • IC 50 value ( ⁇ g/ml) a b c 27 49 180 44 28 76 280 150 29 35 > 1000 > 1000 30 110 540 190 31 180 560 520 32 320 540 540 40 160 > 1000 > 1000 46 110 22 190 48 120 >1000 430 49 11 32 41 50 52 180 380 103 780 > 1000 >1000 109 550 740 > 1000
  • spleen B cells Using murine spleen B cells, the effects of the compound of the formula (I) on the IgGl, IgM and IgE antibody production induced by the stimulation by LPS (lipopolysaccharide; Product No. 520.02051, manufactured by Wako Junyaku) and IL4 (interleukin 4), were studied. Namely, spleen cells of a BALB/c mouse were treated with a murine anti-Thy-l antibody (obtained from Chiba University) and a rabbit complement (Product No.
  • LPS lipopolysaccharide
  • IL4 interleukin 4
  • the amount of each antibody in the cell culture supernatant hereby obtained was measured by the following enzyme-immunoassay. Firstly, on a microplate with 96 wells, 1 ⁇ g/ml of a rabbit anti-mouse IgGl antibody (Product No. 36243, manufactured by Cappel), 1 ⁇ g/ml of a goat anti-mouse IgM antibody (Product No. 0611-0201, manufactured by Cappel) or 10 ⁇ g/ml of a rat anti-mouse IgE monoclonal antibody (Product No.
  • IC 50 value ( ⁇ g/ml) IgG1 IgM IgE c 1 37 25 32 69 2 300 250 370 > 1000 3 2.4 ⁇ 0.001 0.024 130 4 100 56 11 160 5 300 170 71 150 6 450 330 210 270 7 330 410 180 89 8 810 340 310 >1000 9 790 720 320 >1000 10 ⁇ 0.001 ⁇ 0.001 ⁇ 0.001 68 11 16 28 32 210 12 24 0.11 28 560 13 ⁇ 0.001 ⁇ 0.001 0.32 330 14 10 0.89 3.7 500 15 220 78 320 310 16 41 20 50 170 17 1. 0 100 3. 2 510 18 ⁇ 0.
  • mice of 6 weeks old Male DBAl/J mice of 6 weeks old were used in groups each consisting of four mice.
  • the compound of the formula (I) (50 mg/kg) was administered every day for 4 weeks intraperitonially or orally once a day, whereby the change in the body weight and the mortality were examined. As a result, there was no remarkable change in the body weight, and there was no case of death.
  • the LD 50 value of the compound of the above formula (I) is 50 mg/kg at the minimum.
  • the enopyranose derivative of the formula (I) or its salt has an anti-inflammatory activity, and a test example for the anti-inflammatory activity will be given below.
  • a test for an anti-inflammatory activity was conducted by means of carrageenan-induced paw edema model which is commonly used for evaluation of the effectiveness of a common anti-inflammatory agent (NSAID).
  • NSAID common anti-inflammatory agent
  • test compound 0.1 ml of a 1% ⁇ -carrageenan solution was injected intradermally at the sole of the right paw of a SD male rat (six weeks old). Three hours later, the sole volumes of paws on both sides were measured, and the difference in the volume between the right paw and the left paw was taken as the degree of edema.
  • the test compound was orally administered in an amount of 1 ml/100 g (body weight) one hour prior to the administration of carrageenan. To the control group, a physiological saline was administered in the same amount. The results are shown in Table 16.
  • test compounds showed statistically significant suppressing effects against carrageenan-induced paw edema, whereby the effectiveness as anti-inflammatory agents was confirmed.
  • the enopyranose derivative of the formula (I) or its salt is administered orally or non-orally usually at a dose of from about 50 mg to 5,000 mg per day for an adult, although the dose may vary depending upon the conditions for administration, etc.
  • the administration of the drug can be conducted per orally, intravenously, intramuscularly, intradermally or permucassaly.
  • Formulations for administration include, for example, powders, microgranules, granules, tablets, pills, capsules, injection solutions, nose drops, suspensions, intravenous drips, ointments, syrups and gradually releasing agents. These formulations can be prepared by conventional methods by using pharmaceutically acceptable common carriers in the same manner as for usual drug formulations.
  • the present invention provides an immuno-suppressive agent containing a compound of the formula (I) as an effective component. More specifically, the immuno-suppressive agent of the present invention is effective for treatment of a disease caused by abnormal sthenia of an immunological function, for example, an autoimmune disease such as rheumatoid arthritis, systemic lumpus erythematosus, chronic nephritis, chronic thyroiditis or autoimmune hemolytic anemia as well as for suppressing a rejection at the time of transplantation of an organ. Further, it is effective for treatment of an allergy disease or an inflammatory disease, particularly for treatment of an autoimmune disease such as rheumatoid arthritis.
  • an autoimmune disease such as rheumatoid arthritis, systemic lumpus erythematosus, chronic nephritis, chronic thyroiditis or autoimmune hemolytic anemia
  • an allergy disease or an inflammatory disease particularly for treatment of an autoimmune disease such as rheumatoid arthritis.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP93101822A 1992-02-06 1993-02-05 Immuno-suppressing enepyranose derivatives Expired - Lifetime EP0560055B1 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP6658292 1992-02-06
JP6658292 1992-02-06
JP66582/92 1992-02-06
JP36175292 1992-12-16
JP4361752A JPH06183965A (ja) 1992-12-16 1992-12-16 免疫機能抑制剤
JP361752/92 1992-12-16

Publications (2)

Publication Number Publication Date
EP0560055A1 EP0560055A1 (en) 1993-09-15
EP0560055B1 true EP0560055B1 (en) 2002-08-28

Family

ID=26407775

Family Applications (1)

Application Number Title Priority Date Filing Date
EP93101822A Expired - Lifetime EP0560055B1 (en) 1992-02-06 1993-02-05 Immuno-suppressing enepyranose derivatives

Country Status (6)

Country Link
US (1) US5380834A (zh)
EP (1) EP0560055B1 (zh)
CN (1) CN1041167C (zh)
AT (1) ATE222919T1 (zh)
DE (1) DE69332232T2 (zh)
ES (1) ES2184733T3 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI244484B (en) * 1998-06-09 2005-12-01 Takara Bio Inc Pharmaceutical composition containing oxy-containing hexacyclic compound
CN112778386A (zh) * 2021-03-12 2021-05-11 中南民族大学 一种具有免疫抑制活性的化合物Ldj-29及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4256646A (en) * 1978-06-29 1981-03-17 The United States Of America As Represented By The Department Of Health, Education And Welfare Synthesis of optically pure thromboxanes
JPH04316593A (ja) * 1991-02-21 1992-11-06 Japan Tobacco Inc Ｄ−アロサンの製造方法

Also Published As

Publication number Publication date
ATE222919T1 (de) 2002-09-15
DE69332232D1 (de) 2002-10-02
CN1075635A (zh) 1993-09-01
CN1041167C (zh) 1998-12-16
EP0560055A1 (en) 1993-09-15
ES2184733T3 (es) 2003-04-16
US5380834A (en) 1995-01-10
DE69332232T2 (de) 2003-12-11

Similar Documents

Publication Publication Date Title
KR100281264B1 (ko) 신규한 스핀고당 지질 및 그의 사용
US5663151A (en) Sulfated α-glycolipid derivatives as cell adhesion inhibitors
CA2493690C (en) Synthetic c-glycolipid and its use for treating cancer, infectious diseases and autoimmune diseases
US5763413A (en) Lewis-associated compound, process for producing the same, and anti-inflammatory
US4683222A (en) N-glycosylated carboxamide derivatives and their use for influencing the body's inherent defences
US4710491A (en) N-glycosylated carboxylic acid derivatives as agents for combating rheumatic diseases
CZ298895A3 (en) Compound analogous to sialyl lex, pharmaceutical composition containing thereof and process for preparing lactosammonium salt
EP0801071A1 (en) Lewis x derivative and process for producing the same
US6518248B1 (en) Method of treating gastric or colon cancer by administration of a sulfoquinovosylacylglycerol ester
KR920000646B1 (ko) 플루오로-치환 에피포도필로톡신 배당체
EP0560055B1 (en) Immuno-suppressing enepyranose derivatives
US5006647A (en) Phosphorus containing disaccharide derivatives
WO2008069303A1 (ja) フラノース誘導体の製造方法
JP4555466B2 (ja) 置換されたテトラヒドロピラン誘導体、それらの製造方法、医薬または診断剤としてのそれらの使用およびそれらを含有する医薬
US5134230A (en) 2-Deoxy-2-aminoglucopyranoside derivatives
JPH07179490A (ja) エスクレチン誘導体、その製造方法及び軟骨保護剤
Singh et al. An efficient access to protected disialylated glycohexaosyl threonine present on the leukosialin of activated T-lymphocytes
JP3740018B2 (ja) 新規なスルホフコシルアシルグリセロール誘導体およびその医薬としての用途
CA2087805C (en) Immuno-suppressing agent
CA2142153A1 (en) Sulfated .beta.-glycolipid derivatives as cell adhesion inhibitors
Radhi et al. Design, synthesis and A-glucosidase inhibitors evaluation of novel barbiturates based on carbohydrate
CA2019972C (en) Lipid a analogs having immunoactivating and anti-tumor activity
JP3174189B2 (ja) 免疫機能抑制剤
PT1252171E (pt) Processo para a preparação de derivados funcionalizados de beta-(1, 3)-glucanos
JPH06183965A (ja) 免疫機能抑制剤

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17P Request for examination filed

Effective date: 19931105

17Q First examination report despatched

Effective date: 19970624

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20020828

Ref country code: LI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20020828

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20020828

Ref country code: CH

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20020828

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20020828

REF Corresponds to:

Ref document number: 222919

Country of ref document: AT

Date of ref document: 20020915

Kind code of ref document: T

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REF Corresponds to:

Ref document number: 69332232

Country of ref document: DE

Date of ref document: 20021002

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20021128

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20021128

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20021210

ET Fr: translation filed
NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20030205

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20030205

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20030228

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2184733

Country of ref document: ES

Kind code of ref document: T3

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20030530

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20060201

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20060202

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20060220

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20060228

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20060317

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20060410

Year of fee payment: 14

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20070205

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20071030

BERE Be: lapsed

Owner name: *ISHIHARA SANGYO KAISHA LTD

Effective date: 20070228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070901

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070205

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070228

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20070206

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070206

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070205